This page features the latest news about the Revolution Med stock. Revolution Medicines executive sells over $58k in company stock In a recent transaction, Jeff Cislini, the General Counsel of ...

Revolution Medicines (RVMD) announced preliminary safety and antitumor data for RMC-9805, its RAS G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma ...

Revolution Medicines, Inc. ( (RVMD)) has released its Q3 earnings. Here is a breakdown of the information Revolution Medicines, Inc. presented to its investors. Revolution Medicines, Inc.